Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIRPanc: Neoadjuvant Therapy Targeting Adenosine Pathway + ICB + SBRT in Pancreatic Cancer
NCT06048484Phase 2Recruiting
- Start
- May 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of quemliclustat, etrumadenant in pancreatic ductal adenocarcinoma (PDAC). Started May 2024; status: recruiting.
02
Drugs
quemliclustatetrumadenant
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06048484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06048484.